Apyx Medical Corporation reports news on its surgical aesthetics medical-device business, including products marketed as Renuvion, the AYON Body Contouring System, and J-Plasma. Updates commonly cover FDA 510(k) clearances, body contouring capabilities, controlled-heat tissue applications, commercial activity in cosmetic surgery and hospital surgical markets, and OEM agreements with other medical device manufacturers.
The company’s recurring financial releases discuss revenue by its Surgical Aesthetics and Original Equipment Manufacturing segments, product demand for generators and single-use handpieces, U.S. and international sales trends, and management conference participation.
Apyx Medical (NASDAQ: APYX) reported third-quarter 2026 revenue of $14.0 million, up from the same quarter a year earlier. Revenue rose 9.0%, with Surgical Aesthetics sales increasing 17.2% to $12.970 million and OEM sales falling 41.5% to $1.060 million. Net loss attributable to stockholders narrowed to $1.785 million, or $0.04 per share, from $1.984 million, or $0.05 per share. Adjusted EBITDA, a non-GAAP earnings measure, turned positive at $0.4 million versus a $0.1 million loss.
The company reaffirmed its 2026 revenue outlook of $59.0 million to $60.0 million and lowered expected operating expenses to $41.0 million–$42.5 million from less than $45.0 million. It began the full commercial launch of AYON’s reusable power liposuction handpiece during the quarter, following FDA clearance earlier in 2026. Quarterly operating cash use fell to $1.6 million from $3.5 million.
Apyx Medical (APYX) will release its third-quarter fiscal 2026 financial results before markets open on November 5, 2026. Management will discuss the results on a conference call at 8:00 a.m. Eastern Time that day, followed by a question-and-answer session. A live webcast will be available through the company’s Investor Relations website and archived for future reference.
Apyx Medical (NASDAQ:APYX) announced management presentations at two investor conferences, with appearances scheduled for November 9 and November 11, 2026.
Management will join a fireside chat at the UBS Global Healthcare Conference in Miami on November 9 at 10:15am ET. It will present at Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum in New York on November 11 at 10:30am ET. Management will also host one-on-one investor meetings on both days. Both sessions will have live webcasts, with replays available in the Events section of the company's investor relations website.
Apyx Medical (APYX) reported results from a prospective clinical study of Renuvion’s effects on markers of skin quality.
The single-arm, post-market study evaluated seven facelift patients at two U.S. sites; six completed the Day 180 visit. Untreated areas served as controls. At Day 180, treated tissue showed a 30% increase in elastin fiber density, a 55% increase in elastin staining intensity, a 27% increase in the incidence of elastin expression and a 34% reduction in inflammation versus control tissue.
All six participants showed improvement on physician- and patient-assessed aesthetic scores. All reported better skin elasticity, radiance and youthfulness, were satisfied with their outcomes and said they would recommend the procedure. No significant fibrosis, abnormal vascularization or epithelial disruption was observed in treated tissue. The study was published in Plastic and Reconstructive Surgery—Global Open.
Apyx Medical (NASDAQ: APYX) reported second quarter 2026 revenue of $13.9 million, up 22% year over year, driven by 28% growth in the Surgical Aesthetics segment to $12.4 million, while OEM revenue declined 12% to $1.5 million. Gross margin improved to 63.9%, and net loss attributable to stockholders narrowed to $3.2 million ($0.07 per share) from $3.8 million. Adjusted EBITDA loss improved to $0.7 million from $2.0 million.
The company highlighted expanded FDA 510(k) clearance for the AYON Body Contouring System to include power liposuction and a limited launch of the reusable power liposuction handpiece, as well as new retrospective and cellulite/skin laxity clinical data for Renuvion and Avéli combination treatments. Apyx ended the quarter with $27.6 million in cash and cash equivalents and reaffirmed 2026 revenue guidance of $59–60 million, including $54–55 million from Surgical Aesthetics and about $5 million from OEM, while expecting 2026 operating expenses to remain below $45 million.
Apyx Medical (NASDAQ:APYX) announced that its management will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston, MA, on Tuesday, August 11, 2026. President and CEO Charlie Goodwin and CFO Matt Hill will join a fireside chat at 2:30pm ET and hold one-on-one investor meetings.
The fireside chat will be available via live webcast, with a replay posted in the Events section of Apyx Medical’s Investor Relations website. Apyx Medical highlights its Renuvion, AYON Body Contouring System, and J-Plasma technologies, which it describes as supported by more than 90 clinical documents and used in cosmetic and hospital surgical markets.
Apyx Medical (NASDAQ: APYX) will release its financial results for the second quarter of fiscal year 2026 after market close on Thursday, August 6, 2026. Management will host a conference call at 4:30 p.m. Eastern Time the same day to discuss the results and hold a Q&A session.
Investors can join by phone using access code 53282 at 800-717-1738 (U.S.) or 646-307-1865 (international), or via a live webcast available through the company’s Investor Relations website, where a replay will be archived.
Apyx Medical (NASDAQ:APYX) is returning to Miami Swim Week 2026 with its Body by Apyx runway showcase, featuring real Renuvion® patients and body contouring transformations. The company is highlighting AYON Body Contouring System, which integrates Renuvion, advanced liposuction modalities, infiltration, aspiration and electrocautery in one platform.
According to Apyx Medical, AYON offers precision, workflow efficiency and real-time LIFT Technology, while Renuvion and J-Plasma® are supported by more than 90 clinical documents and FDA-cleared indications in aesthetic and surgical markets.
Apyx Medical (Nasdaq: APYX) reported new peer-reviewed clinical data on a minimally invasive combination treatment using Avéli and Renuvion for cellulite and skin laxity.
In 22 patients treated in a single session, up to 81.8% showed cellulite appearance improvement at 180 days, with objective 3D dimple reductions and histologic evidence of increased collagen, elastin and progressive tissue remodeling.
Apyx Medical (NASDAQ: APYX) reported a retrospective 113‑patient study of liposuction with and without Renuvion. Adding Renuvion showed higher Body‑Q satisfaction with excess skin (87.8 vs. 73.8) and abdominal appearance (68.8 vs. 45.0), over 50% lower abdominoplasty rates (30.0% vs. 67.1%), lower revision rates (12.0% vs. 37.5%), and similar complication rates (2.5% vs. 2.7%) versus power‑assisted liposuction alone over more than 12 months of follow‑up.